| ID | 1108 |
| Name of the vaccine | EV 76 NIIEG |
| Microbe | Bacteria |
| Disease name | Plague |
| Name of bacteria | Yersinia pestis |
| Type of vaccine | Live attenuated |
| Nucleic acid content | Circular DNA |
| Age | 20 to 69 years |
| Description of the vaccine | Live whole cell vaccine used in the countries of the Former Soviet Union (FSU) and some Asian countries. |
| Name of the manufacturer | NA |
| Name of the manufacturing country | NA |
| Year of manufacture | Mid 1930 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Single dose as annual routine vaccination. |
| Mechanism of action | NA |
| Route of administration | Percutaneous |
| Indications | Administered yearly in springtime among people living in plague-enzootic areas. |
| Export | Not commercially available in United States and Europe. |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | Yes (enzootic from wild rodents and their fleas) |
| PubMed identifier | 31199832, 24372254 |
| Clinical trial number | NA |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|